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Abstract
Background: Helicobacter pylori elicited IL1B is one of the various modulators responsible for perturbation of acid secretion
in gut. We have earlier reported that IL1B activated NFkB downregulates gastrin, a major modulator of acid secretion.
However, we hypothesized that regulation of gastrin by IL1B would depend on the cell’s ability to integrate inputs from
multiple signaling pathways to generate appropriate biological response.
Principal Finding: In this study, we report that IL1B induces Smad 7 expression by about 4.5 fold in gastric carcinoma cell
line, AGS. Smad 7 resulted in transcriptional repression of gastrin promoter by about 6.5 fold when co -transfected with
Smad 7 expression vector and gastrin-promoter luciferase in AGS cells. IL1B inhibited phosphorylation of Smad 3 and
subsequently interfered with nuclear translocation of the positive Smad complex, thus occluding it off the gastrin promoter.
IL1B promoter polymorphisms (-511T/-31C IL1B) are known to be associated with H. pylori associated gastro-duodenal ulcer.
We observed that IL1B expressed from -31T promoter driven IL1B cDNA elicited 3.5 fold more Smad 7 than that expressed
from the IL1B-31C variant in AGS cells. This differential activation of Smad 7 by IL1B promoter variants translated into
differential downregulation of gastrin expression. We further analyzed Smad 7, NFkB, IL1B and gastrin expression in antral
gut biopsy samples of patients with H. pylori associated duodenal ulcer and normal individuals. We observed that
individuals with duodenal ulcer had significantly lower levels of IL1B, Smad 7, NFkB and corresponding higher level of
gastrin expression.
Conclusion: Pro-inflammatory cytokine IL1B repress gastrin expression by activating Smad 7 and subsequent inhibition of
nuclear localization of Smad 3/4 complex. Polymorphic promoter variants of IL1B gene can modulate the IL1B expression
which resulted in differential activation Smad 7 and consequent repression of gastrin expression, respectively. Analysis of
H. pylori infected duodenal ulcer patient’s gut biopsy samples also supported this observation.
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Introduction
Almost half of the world’s population harbors Helicobacter pylori
infection in the gastric mucosa [1]. A significant proportion of
these infected individuals develop clinically relevant gastritis and
some of these proceed to develop either gastric ulcers, gastric
carcinoma or a low grade B- cell lymphoma [2,3]. About 10–15%
of individuals chronically infected with H. pylori develop antral
predominant gastritis that predisposes them to develop duodenal
ulcer [4]. Duodenal ulcer is characterized by increased basal and
stimulated acid secretion which results due to perturbation of its
major modulators, the gastrin-somatostatin hormone axis [5].
Pentagastrin-stimulated peak acid output, an indicator of func-
tional parietal cell mass, is increased in H. pylori infected duodenal
ulcer patients [6]. Gastrin Releasing Peptide-stimulated peak acid
output, an indicator of the stomach’s functional response to
endogenous gastrin is also increased in these patients [6]. The
mechanism of regulation of acid secretion on H. pylori infection
remains unknown, but various reports suggest that cytokines might
play a major role in this regulation [7]. The gastric mucosal
inflammatory response to H. pylori involves increased synthesis of
cytokines like IFN-c, TNF-a, Interleukin -12 (IL12) and
Interleukin 1Beta (IL1B) [8]. Genetic studies have suggested that
polymorphisms in these genes are associated with H. pylori
mediated gastro duodenal diseases [9,10]. However, the molecular
cue by which theses immunological messengers affect the
downstream mediators of acid modulation is not well established.
It has been reported that Interferon-c suppresses somatostatin
expression resulting in inhibition of IL4 production, which
otherwise is stimulated by somatostatin to reverse H. pylori-induced
gastritis [11]. The pro-inflammatory cytokine IL1B is known to
negatively affect acid secretion in gut [12,13,14]. In vivo studies in
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phisms are related to hypochlorhydria and increased risk of gastric
cancer in the presence of H.pylori infection [9].
We have previously reported that pro-inflammatory cytokine
IL1B down-regulates gastrin via NFkB in a dose dependent
manner [12]. This IL1B mediated gastrin inhibition was found to
be reversed to about 40% by pharmacological or peptide
inhibitors of NFkB [12]. Thus, inhibition of NFkB activation did
not totally abrogate IL1B mediated gastrin repression. It is well
established that such biological response of a gene by an upstream
stimuli would depend upon integration of a number of pathways.
The partial recovery of gastrin expression by NFkB inhibitors thus
indicated the possibility of other independent IL1B mediated
repression pathways [10]. In the present study, we have delineated
an alternative orchestra of signaling events that would also lead to
IL1B mediated attenuation of gastrin expression. We have also
validated our observation in gut biopsy samples of H. pylori infected
duodenal ulcer patients.
Materials and Methods
Subjects
The subjects included in this study were 20 unrelated
individuals, [H. pylori infected individuals with duodenal ulcer
(HP+U+=12), H. pylori infected asymptomatic individuals
(HP+U2=8)] who attended routine endoscopy at the SSKM
hospital, Kolkata, India from August 2007 to April 2008. Gastric
antral biopsy samples were collected from these individuals and
further molecular and biochemical analysis was done. H. pylori
status of the subjects was detected by rapid urease test, and
confirmed by microscopy and PCR analysis for bacteria specific
CAG pathogenicity region from the gastric biopsy samples (data
not shown). The diagnosis of duodenal ulcer was established on
the basis of conventional clinical and endoscopic findings. No
subject had received treatment for H. pylori infection. Patients
taking non-steroidal anti-inflammatory drugs or receiving antise-
cretory therapy, as well as those with gastric carcinoma were
excluded from the study. Duodenal ulcer patients with gastroin-
testinal bleeding or suffering from osteoarthritis, cardiovascular
diseases were also excluded. The biopsy samples were homoge-
nized in Trizol (Invitrogen, Life Technologies, Carlsbad, USA) for
RNA preparation. Smad 7 and IL1B expression levels were
analyzed in these samples by real time PCR. The biopsy tissue
from same individuals were also homogenized in Lysis buffer (Tris,
pH 8.0, EDTA, NaCl, NP40, Triton X, Protease inhibitor
cocktail) and subjected to either ELISA or Western blot analysis
for estimation of gastrin (G-17) (Gastrin ELISA KIT, Assay Design
Inc., Ann Arbor, USA) and NFkB respectively. The protein was
estimated by Bradford reagent (Sigma Aldrich, St. Louis, USA)
according to manufacturer’s protocol.
Ethics statement
Prior to sample collection, written informed consent was
obtained from each individual, which was approved by the Ethical
Committee of the SSKM hospital, Kolkata.
Cell Culture, transfection and treatment with IL1B, TGF
beta, NBD, si-RNA
AGS cells, (3.2610
6) maintained in RPMI 1640 medium (Gibco
BRL, Life Technologies, Grand Island, USA) were transiently
transfected in duplicates with different amounts of DNA as
required for the specific experiment by using Lipofectamine2000
Reagent (Invitrogen, Life Technologies, Carlsbad, USA) accord-
ing to the manufacturer’s protocol. PGL3 control vector
(Promega, Madison, USA) was used as control for luciferase assay
and beta-galactosidase plasmid vector (Promega, Madison, USA)
was used as transfection control. AGS cells were treated with
varying amounts (0–10 ng/ml) of recombinant IL1B (Sigma
Aldrich, St. Louis, USA) for two and a half hours and harvested
for RNA preparation, luciferase assay and Western blot analysis.
AGS cells were also treated with 6 ng/ml TGF beta (eBioscience
Inc, San Diego, USA) for 20 hours. AGS cells were incubated with
150 mM/ml of nemo binding inhibitory peptide (NBD) (Calbio-
chem-Novabiochem, San Diego, USA) after 24 hours of transfec-
tion and harvested for luciferase and Western blot analysis after
24 hours of NBD treatment. Various siRNA constructs directed
against Smad 7 (sc-36508, Santa Cruz Biotechnology, CA and
scrambled control (Ambion) were used at a final concentration of
80 nM.
Quantitative Real Time PCR
RNA was prepared from recombinant IL1B treated AGS cells
according to the manufacturer’s protocol by Trizol method
(Invitrogen, Life Technologies, Carlsbad, USA). cDNA was
prepared by random hexamer (Invitrogen, Life Technologies,
Carlsbad, USA) using MMLV RT (Promega, Madison, USA). Smad
7 and IL1B mRNA expression was determined by real time RT
PCR in the ABI 7500 Fast (Applied Bio-systems Inc, Life
Technologies, Foster City, USA) using the SYBR green technology
(Applied Biosystems Inc, Life Technologies, Foster City, USA). The
primers used are as follows: SMAD7 forward (F), 59-GCCTCGGA-
CAGCTCAATTCG-39 and reverse (R), 59-CGTCCACGGCTG-
CTGCATAA-39; IL1B forward (F) 59-AAACAGATGAAGT-
GCTC CTTCCAGG-39 and reverse (R), 59-TGGAGAACAC-
CACTTGTTGCTCCA-39, Beta-actin forward (F), 59-GGATGCA-
GAAG GAGATCACTG-39, and reverse (R), 59-CGATCCA
CACGGAGTACTTG-39. Threshold cycle CT of duplicate
samples was determined using the ABI 7500 Fast software (Applied
Biosystems Inc, Life Technologies, Foster City, USA). The level of
Smad 7 and IL1B was normalized to Beta -actin levels by calculating
the D CT value which is the CT (threshold cycle) of the endogenous
control (Beta-actin) subtracted from the CT of the target gene (Smad
7/IL1B). The fold difference in Smad 7 and IL1B expression
calculated using the formula 2
–DDCT.
Western Blot analysis
Equal amount of total protein prepared from IL1B treated AGS
cells (3.2610
6 cells) were subjected to Western blot analysis using
antibodies against Smad 7, p-Smad 3, Smad 3 (Santa Cruz
Biotechnology Inc, Santa Cruz, USA), or Beta -actin (Sigma
Aldrich, St. Louis, USA). The immuno complex was detected by
staining with HRP-conjugated secondary antibody (Sigma Al-
drich, St. Louis, USA). The band intensities were quantified by
using the image analysis software ImageJ (http://rsb.info.nih.gov/
ij/index.html). The integrated density of each band was
normalized to the corresponding human Beta-actin band.
Immunofluorescence Assay
For immunefluorescence studies, AGS cells were cultured on
coverslips placed in 35 mm plates. The cells were incubated with
varying concentrations of recombinant IL1B protein for 30
minutes and then washed with phosphate buffered saline (PBS).
The coverslips were overlaid with methanol fixative for 20 minutes
at –20uC. Then cover slips were washed with PBS and cells were
permeabilized with 0.5% Triton-X in PBS for 25 minutes at room
temperature, and nonspecific binding sites were blocked with 1%
bovine serum albumin in PBS. Finally the cells were washed with
PBS and incubated with rabbit polyclonal antibody against Smad
Smad 7 Down Regulates Gastrin
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dilution, for overnight. Cells were washed with PBS to remove
unbound antibody, and bound rabbit immunoglobulin G (IgG)
was detected with goat anti-rabbit IgG-fluorscein isothicyanate
(FITC) conjugate (Santa Cruz Biotechnology Inc, Santa Cruz,
USA) used at 1:400 dilution. Unbound conjugate antibody was
removed by washing in PBS. Stained cells were mounted with
sodium phosphate buffer containing 10% glycerol and DABCO
(Sigma Aldrich, St. Louis, USA) as an antiquencher and examined
at 40X in fluorescence microscopy LSM-510 (Carl Zeiss,
Germany).
Luciferase Assay
The cells were lysed in the luciferase cell culture lysis buffer
provided with the Luciferase Assay Kit (Promega, Madison, USA)
and 15 ml of supernatant was analyzed for firefly luciferase activity.
Luminescence was measured as relative light units (RLU), taking
the reading of luciferase assay substrate alone and then with lysate
in GlowMax 20/20 luminometer (Promega, Madison, USA). The
total protein concentration in each lysate was determined with a
protein assay kit (Sigma Aldrich, St. Louis, USA) and subsequently
used to normalize the luciferase activity. Transfection normaliza-
tion was done by beta galactosidase assay. Measurements of mean
6 S.D were taken in triplicates and represented graphically on a
MS-Excel sheet.
ELISA
The cell lysates were analyzed for gastrin (gastrin-17 polypep-
tide) protein by enzyme linked immunoabsorbent assay (ELISA).
For ELISA the Gastrin Immuno assay kit (Assay Design Inc, Ann
Arbor, USA) were used following the manufacturer’s instructions.
The total protein concentration in each sample was estimated by
Figure 1. Deletion mapping of 240bp human gastrin promoter for IL1B responsive elements. (A) Schematic diagram of serial deletion of
putative gastrin promoter cloned upstream of luciferase reporter gene. The boxes and circle represent different transcription factor binding sites
within the 240 bp gastrin promoter. The line diagrams depict the different deletion clones used for the study. (B) The fold inhibition in luciferase
activity of different deletion constructs of the gastrin promoter in AGS cells in presence and absence of recombinant IL1B (10 ng/ml). AGS cells were
transfected with respective gastrin promoter deletion constructs. Forty-six hours after transfection, cells were either treated or left untreated with
10 ng/ml of IL1B for two hours and then harvested. Luciferase activity was measured and the average fold differences between the treated and
untreated sets were plotted from three different experiments.
doi:10.1371/journal.pone.0014775.g001
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subsequently used to normalize the gastrin value obtained by
ELISA.
Results
Minimal gastrin promoter contains Smad 3 binding
elements
To identify additional signaling pathways we analyzed the
luciferase activity of a series of 59- deletion mutants of gastrin
promoter in presence and absence of recombinant IL1B (10 ng/ml)
in AGS cells (Fig. 1A). It was observed that there was steady release
of IL1B mediated repression upon serial deletion of the gastrin
promoter. On deletion of 90 bp (pGas-150 Luc) from the full length
240 bp (pGas-Luc) gastrin construct, IL1B mediated gastrin
repression reduced from 11 fold in pGas-Luc to 6.3 fold in pGas-
150 Luc. Moreover, despite the deletion of NFkB binding site
(pGas-117 Luc) present within 2150 nt to 2117 nt there was a 3.6
-fold repression of luciferase activity in presence of IL1B, indicating
the presence of other IL1B responsive elements in these regions
(Figure 1B). A promoter scan (http://www.gene-regulation.com/
pub/programs.html) revealed presence of three putative Smad 3
binding sites in the 240 bp promoter region of human gastrin
which might respond to IL1B signaling (Fig. 1A). A previous
report stated that a Smad binding element is present in the
murine gastrin promoter near its transcription start site [15].
Moreover, gastrin promoter sequence alignment revealed that
there is 87% homology in a region just upstream of the start
site between murine and human sequences (data not shown). It
has been reported that murine gastrin promoter is activated by
Smad 3/4 transcription factor [15]. There are also reports that
IL1B is able to inhibit Smad 3 responsive genes by inducing
Smad 7 ([16,17,18]. Therefore, we next looked into the role of
Smad 7 in IL1B mediated gastrin repression.
IL1B inhibits nuclear translocation of Smad 3/Smad 4
complex by inducing Smad 7 in AGS cells
We investigated the effects of IL1B on Smad 7 protein and
mRNA expression in AGS cells. IL1B was found to significantly
up-regulate both Smad 7 mRNA and protein in a dose dependent
manner (Fig. 2A and B). It is known that the activated Smad 7
represses Smad 3 responsive gene by inhibiting phosphorylation of
the Smad 3 thus interfering with formation of activated Smad 3/4
complex [19]. In the present study we also observed reduced
phosphorylation of Smad 3 upon treatment of AGS cells with
IL1B (Fig. 3A). However, the total cellular Smad 3 levels remained
unaltered (Fig. 3A). One of the key downstream effectors of IL1B
signaling pathway is TAK1. Thus, we ectopically expressed
pCMVF TAK1 along with its activator TAB1 to show that it also
inhibits phosphorylation of Smad 3 in AGS cells (Fig. 3B). Finally,
we showed reduced nuclear localization of Smad 3/Smad 4
complex upon treatment of AGS cells with IL1B due to less
phosphorylation of Smad 3 (Fig. 3C). Similar results were obtained
in AGS cells co-transfected with pCMVF TAK1 along with its
activator TAB1 (data not shown).
IL1B activated Smad 7 represses gastrin expression
We employed two separate approaches to confirm whether
IL1B activated Smad 7 had indeed any effect on gastrin expression
(Fig. 4). We co-transfected pGas-Luc with different doses of Smad
7 expression vector in AGS cells and observed that there was a
dose dependent decrease in gastrin promoter activity with
increasing concentration of Smad 7 expression vector (Fig. 4A).
To further validate this finding, we first checked whether gastrin
promoter responds to the TGF beta signaling in AGS cells. As
shown in Fig. 4B gastrin promoter driven luciferase activity was
increased when Smad 3 was ectopically expressed in presence of
TGF beta in AGS cells. Next, we co-transfected Smad 3 along
with Smad 7 and gastrin luciferase (pGas-Luc) and stimulated
AGS cells with TGF beta (6 ng/ml) for 20 hours. We found that
stimulation of AGS cells with TGF beta along with overexpression
of Smad 3 could alleviate the negative effect of Smad 7 on gastrin
luciferase to a significant extent (Fig. 4C). This observation
confirms that gastrin luciferase is negatively regulated by Smad 7.
Moreover, we can also conclude that the regulation of gastrin
depends on the relative molecular abundance of Smad 3 and
Smad 7. Previously Chakravorty et al (2009) had reported that
Il1B mediated gastrin repression involves NFkB [12]. To
investigate the relative contribution of NFkB and Smad7 in
IL1B mediated negative regulation of gastrin; we inhibited NFkB
activity by its pharmacological inhibitor Nemo Binding Peptide
(NBD) or knocked down Smad7 expression by using siRNA
against Smad7 and observed its effect on the gastrin promoter. We
found that either NFkB or Smad7 inhibitors alone are able to
release IL1B mediated gastrin repression by almost about 35%
(Fig. 4D). Further, simultaneous inhibition of both these pathways
lead to release of the repression by almost about 60% (Fig. 4D).
This observation led us to conclude that both these pathways are
contributing equally to bring about gastrin repression (Fig. 4D).
IL1B promoter variant induced Smad 7 differentially
downregulates gastrin expression
Previously we reported that IL1B downregulates gastrin in a
promoter variant specific manner and that this differential
downregulation is partly due to differential induction of the
intermediary signaling molecule NFkB [12]. To investigate similar
differential effect of IL1B promoter variants on Smad 7 expression,
we co-transfected beta galactosidase plasmid along with equal
amount of IL1B -31C or IL1B -31T promoter driven IL1B
expression vectors (pMC-IL1B-31C and pMC-IL1B-31T) in AGS
cells and Western blot analysis was done with anti-Smad 7
antibody. We observed a 3.5 fold increased activation of Smad 7
expression when IL1B was expressed from IL1B -31T than IL1B-
31C expression vector (Fig. 5A). We next established that the
differentially expressed IL1B from variant IL1B promoters could
downregulate gastrin in a predictable pattern through differential
activation of Smad 7 in NFkB independent manner (Fig. 5B). We
co-transfected AGS cells with pGas-Luc and either pMC-
31CIL1B or pMC-31TIL1B and incubated the cells for 24 hours
in presence or absence of NFkB inhibitor NBD. We observed that
as expected there was IL1B promoter variant specific differential
Figure 2. Dose dependent effect of IL1B upon Smad7 expression. (A) Quantitative analysis of IL1B induced Smad7 mRNA expression. RNA
was extracted from AGS cells treated with variable concentration of recombinant IL1B (0, 2.5, 5, 10 ng/ml) for two hours. Real time PCR analysis for
Smad 7 was performed from cDNA prepared from those samples. Beta-actin was taken as the endogenous control. The graph represents the mean of
relative quantification measured from three different experiments +_ SD. (B) Analysis of IL1B induced Smad 7 protein expression. AGS cells were
treated with increasing concentration of recombinant IL1B protein for two hours and then lysed and immunoblotted with Smad7 antibody. The
bands were scanned by Image J software and normalized band intensity of Smad7 from three different experiments +_ SD was plotted as a
histogram. A representative blot is shown.
doi:10.1371/journal.pone.0014775.g002
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intermediary Smad 7 (Fig. 5B upper panel) even when NFkB
was inhibited (Fig. 5B upper panel).
Next, we sought to understand the clinical significance of
differential Smad 7 expression in H. pylori associated duodenal
ulcer patients. We compared the expression of Smad 7, NFkB,
Figure 3. IL1B inhibits Smad 3 phosphorylation thus perturbing its nuclear localization. AGS cells were treated with increasing
concentration of recombinant IL1B protein for two hours and then lysed and immuno-blotted with (A) phosphorylated Smad3 specific antibody (p-
SMAD 3) and antibody against Smad 3 protein (SMAD 3). A representative blot is shown. (B) AGS cells were co-transfected with different
concentrations pCMV-TAK1 and equal amount of pCMV-TAB1, the two immediate downstream mediator of IL1B, and harvested for immuno-blot
analysis with p-SMAD3 antibody after forty eight hours. A representative blot is shown. (C) Nuclear localization of Smad 3 in AGS cells treated with or
without IL1B (10 ng/ml). In each panel the left section represents FITC conjugated anti-SMAD 3 antibody and the right panel represents the overlay of
DAPI/FITC images captured at that field. The experiment establishes that IL1B inhibits nuclear translocation of Smad 3.
doi:10.1371/journal.pone.0014775.g003
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e14775Figure 4. Effect of Smad 7 on gastrin promoter activity. AGS cells were cotransfected with (A) Gas-Luc construct and increasing amount of
Smad 7 expression vector (B) Gas-Luc construct and Smad 3 expression vector along with treatment with recombinant TGF-beta for 20 hours (C) Gas-
Luc construct and either Smad 7 or both Smad 3 and Smad 7 expression vectors with or without stimulation with recombinant TGF-beta for 20 hours.
Cells were harvested 48 hours after transfection and luciferase activity was measured. The mean luciferase activity of three different experiments is
represented as fold activation or repression with respect to gastrin promoter alone and graphically plotted. These experiments establish that Smad 7
downregulates gastrin (D) AGS cells were transfected with Gas-Luc construct after the treatment with either si-RNA against Smad 7 or Control
scrambled si-RNA for 24 hours. After 44 hours of Gas-Luc transfection, cells were either incubated with NBD (150 mM/ml) or left untreated. Next, cells
were stimulated with recombinant IL1B (10 ng/ml) at 46 hours from Gas-Luc transfection or left untreated. Cells were then harvested 48 hours after
transfection of Gas-Luc and luciferase activity was measured. The mean luciferase activity of three different experiments is represented as fold
activation or repression with respect to gastrin promoter alone and graphically plotted. This experimental observation concludes that both Smad 7
and NFkB pathways contribute equally in IL1B mediated inhibition of gastrin expression. (Inset shows representative Western Blot for Smad7 in Smad
7-siRNA treated and untreated lysates.)
doi:10.1371/journal.pone.0014775.g004
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infected asymptomatic and symptomatic individuals (HP+U2 vs.
HP+U+). Quantitative RT-PCR analysis of Smad 7 mRNA
showed significantly lower expression of Smad 7 in ulcer patients
compared to asymptomatic individuals despite both being infected
with H. pylori (Fig. 6A). Similar result was also obtained in case of
NFkB levels as measured by Western blot analysis of antral gut
biopsy samples from these two groups of individuals (Fig. 6B).
Interestingly, these results corroborated with the expression of
IL1B in the gut biopsy samples of these two groups. H. pylori
associated ulcer patients have significantly lower level of IL1B than
infected asymptomatic individuals (Fig. 6C). Finally, measurement
of antral gastrin levels by ELISA in these two sets of samples
revealed a higher level in HP+U+ samples than that of HP+U2
though it is not statistically significant (Fig. 6D).
Discussion
It has been reported that H. pylori elicited IL1B is one of the
various modulators of the gastrin–somatostain hormone axis
which regulates the acid secretion in gut [7]. In this study, we
illustrate one of the probable pathways by which the proin-
flammatory cytokine IL1B affects gastrin expression. We show that
IL1B induced Smad 7 inhibits the nuclear localization of Smad 3,
thereby bringing about transcriptional repression of Smad 3
dependent gastrin expression. The -31C promoter polymorphism
of IL1B has been reported to be associated with H. pylori mediated
duodenal ulcer in various populations [10]. We also observed that
there was promoter variant specific differential induction of Smad
7 expression and gastrin repression by IL1B. We have further
measured the expression of Smad 7, NFkB, IL1B and gastrin in H.
pylori infected duodenal ulcer patients and asymptomatic individ-
uals and validated our hypothesis that differential expression of
IL1B may lead to differential level of Smad 7 and NFkB causing
altered gastrin level in vivo (Fig. 7).
It is known that IL1B acts as a potent inhibitor of gastric acid
secretion, on a molar basis, and is estimated to be 100-fold more
potent than proton pump inhibitors and 6,000-fold more potent
than H2 antagonists [9]. Kondo et al reported that IL1B is an
extremely effective acid suppressant when given intracisternally
and it also inhibits release of histamine from gastric enterochro-
maffin-like cells [20]. Despite many in vivo studies showing
inhibition of acid secretion by the cytokines, the mechanism of
the inhibition by IL1B is poorly understood. We had previously
reported that IL1B inhibits acid secreting hormone gastrin by
activating NFkB [12]. However, the contribution of NFkB
activation to gastrin downregulation was partial [12]. We
identified Smad 3 binding elements within the 240 bp promoter
region of human gastrin in the present study. It is known that
regulation of Smad 3 is mediated by TGF- beta signaling [21].
TGF beta induced activated TGF-betaRI phosphorylates Smad2
and Smad 3. Phosphorylated Smad 2 and Smad 3 associate with
Smad 4 and translocate to the nucleus where Smad proteins
participate in transcriptional control of target gene [21]. Thus,
disruption of TGF beta signaling would negatively influence Smad
3 target gene gastrin expression [22]. It has been reported that,
TGF beta mediated signalling pathway is impaired in cells with
high expression of Smad 7 because it prevents Smad 2/3
phosphorylation following the binding of active TGF beta 1 to
the receptor [23]. There are several reports which suggests that
pro-inflammatory cytokines like TNF-a, IL1B and IFNc which are
produced in excess in mucosa during H. pylori infection, can
positively influence Smad 7 expression [16,18,24,25,26]. Similarly,
we also observed that in gastric cancer cell line AGS, IL1B
induced Smad 7, inhibits the phosphorylation of Smad 3 and
subsequently interferes with gastrin expression. A previous report
also showed that failure in TGF beta signaling plays an important
role in gut inflammation and is associated with high expression of
Smad 7 [27,28]. Though there are no reports on association of
TGF beta with duodenal ulcer, a positive correlation between
TGF beta expression and gastric ulcer healing has been reported.
Patients with healed gastric ulcers showed an increased expression
of both TGF beta and its receptors while patients with refractory
ulcers had weak or deficient TGF beta expression in the gastric
mucosa, suggesting crucial role of TGF beta in gastric ulcer
healing [29].
Our clinical data suggest that individuals with H.pylori associated
duodenal ulcer have higher expression of gastrin and a correlated
lower expression of NFkB and Smad 7. Higher expression of
gastrin would also lead to higher acid output. The difference in
IL1B expression in H.pylori infected asymptomatic individuals
(Hp+ U2) in comparison to duodenal ulcer patients (HP+U+) can
be attributed to the difference in genetic make up of these
individuals as reported by various association studies. These
studies along with previous data from our lab have reported that
IL1B -31C promoter variant is associated with H. pylori infected
duodenal ulcer. In our previous report, we have also observed that
individuals homozygous for -31C IL1B variant, irrespective of H.
pylori status have lower expression of IL1B than individuals
harboring the alternative genotype [10,12]. However in this study,
we observe that the difference in gastrin expression between
infected symptomatic (HP+U+) and asymptomatic (HP+U2)i s
not statistically significant. This apparent anomaly could be due to
small sample size and/or existence of other IL1B independent
pathway controlling gastrin expression and acid secretion. Thus,
the in vivo scenario with respect to relative levels of Smad 7, NFkB,
IL1B and gastrin in gut biopsy samples of H. pylori infected
asymptomatic and duodenal ulcer patients reflects the in vitro
observation that differential expression of IL1B can modulate
differentially the expression of both Smad 7 (this study) and NFkB
(this study and [12]) which in turn may alter the gastrin levels in
human gut in a predictable manner. This is significant because it
emphasizes that the subtle difference in signaling due to promoter
polymorphisms can alter the course of biochemical pathway
resulting in variation in disease phenotype.
Figure 5. Effect of IL1B promoter polymorphism on Smad 7 expression. (A) IL1B promoter polymorphisms differentially regulate Smad 7
protein expression in AGS cells. AGS cells were transfected with the IL1B promoter-driven luciferase construct having either the C or T allele at the
231 position (the constructs are represented as the line diagram) and cells were harvested after 48 hours for immuno blot with Smad7 antibody. The
band intensity was scanned and normalized with Beta- actin. The normalized band intensity of three different experiments was plotted. (B) IL1B
promoter polymorphisms differentially downregulate gastrin via Smad 7, independent of NFkB pathaway. AGS cells were co-transfected with the IL1B
promoter-driven luciferase construct having either the C or T allele at the 231 position along with pGas-Luc and after 24 hours of transfection cells
were either treated with NBD or left untreated. Beta-Gal plasmid was used as transfection control. Cells were harvested after 48 hours of transfection
for luciferase assay. Protein in each case was normalized by Bradford assay. The normalized mean RLU/mg protein +_ SD of three different
experiments was plotted. The same lysates were also subjected to immunoblot analysis with Smad 7 and NFkB antibody. Beta-actin was used as input
control.
doi:10.1371/journal.pone.0014775.g005
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PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e14775Figure 6. Expression profile of Smad 7, NFkB, IL1B and gastrin in H. pylori infected duodenal ulcer patients (HP+U+) and
asymptomatic individuals (HP+U2). (A) Smad 7 expression is significantly lower in H. pylori infected duodenal ulcer patients (HP+U+) compared
to infected asymptomatic individuals (HP+U2): RNA was extracted from gut biopsy samples of H. pylori infected duodenal ulcer patients
(HP+U+=12) and H. pylori infected asymptomatic individuals (HP+U2=8). Real time PCR analysis for Smad 7 mRNA was performed from cDNA
prepared from those samples. Beta-actin was taken as endogenous control. The mean relative quantification value from each of the group is
represented in the graph. (B) NFkB expression is significantly lower HP+U+ group compared to HP+U-: Gut biopsy samples from both the groups
were homogenized and lysed for immuno blot with NFKB p50 antibody. Beta-actin was used as input control. Bradford assay was used to quantify the
protein and 50 mg was loaded in each well. The mean normalized value from each of the group is represented in the graph. (C) IL1B expression is
significantly lower in HP+U+ group compared to HP+U2: RNA was extracted from gut biopsy samples of both the groups. Real time PCR analysis for
IL1B was performed from cDNA prepared from those samples. Beta-actin was taken as the endogenous control. The mean relative quantification
value from each of the group is represented in the graph. (D) Gastrin expression is moderately higher in HP+U+ group compared to HP+U2: Samples
were homogenized and lysed to measure Gastrin-17 levels by ELISA. Bradford assay was used to quantify the protein. The normalized mean value
obtained from each group is graphically plotted.
doi:10.1371/journal.pone.0014775.g006
Figure 7. IL1B activates two different pathways having a cumulative effect on Gastrin repression. Stimulation with IL1B results in an
increase in Smad7 levels which inhibits the TGF-beta pathway by blocking the nuclear localization of the regulatory Smad 2/3/4 complex. On the
other hand, IL1B also activates the NFKB pathway which plays a direct role in repression of the gastrin gene expression. Dotted arrows represent
pathways that are yet to be established.
doi:10.1371/journal.pone.0014775.g007
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